The chief medical officer of Gain Therapeutics discusses GT-02287, a promising treatment for Parkinson that has shown strong safety and tolerability in an ongoing phase 1 trial. [WATCH TIME: 3 minutes]
Jonas Hannestad, MD, PhD
Advertisement
Articles by Jonas Hannestad, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Targeting Neuroinflammation and Repair: The Rationale Behind Ibudilast
2
Risvodetinib Demonstrates Potential Functional Benefit in Early Parkinson Disease
3
Future Directions and Trial Design Needs in MS
4
Ecopipam Maintains Efficacy and Reduces Relapse Risk in Phase 3 Trial in Tourette Syndrome
5
